All News
ACR 2024 - Day 1 Report
ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.
Read Article
#1474
🔬Severe PsA? Guselkumab (GUS) has promise!
➡️In bionaive pts with severe disease activity,
GUS v. PBO resulted in:
🔴73% improvement in joints
🔴53% lower disease activity
🔴63% better PtGA by 2 years
➡️Rapid results by W2, sustained through W100.
#ACR @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#1326
🔬 Predicting Imminent Inflammatory Arthritis
➡️543 anti-CCP+ at-risk (high/low) tracked
🔑Predictors for IA in high-risk:
🔴EMS≥30min(OR 11)
🔴RF+(OR 6)
🔴US PD(OR 5)
🔴smJTC (OR 5)
🔑Predictors for IA in low risk:
🔴RF+(OR 8)
🔴Anti CCP >3xULN(OR 7)
#ACR24 @RheumNow https://t.co/ou9HNcNb8X
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Half of the respondents chose #IL17i for #psoriatic #arthritis #PsA Rx for #Achilles #tendonitis
Interesting as lots
Of data
On #enthesitis wIL23i
Likely all
Effective #PsA Rx helps #tenosynovitis
some have
➡️ data on #efficacy
⬆️ bio rationale
#ACR24 @RheumNow @ACRheum https://t.co/wzefjsfdaj
Janet Pope Janetbirdope ( View Tweet)
@DrLauraCoates presented Sex differences in clinical presentations of PsA:
-Women present >polyarthritis, enthesitis and worse PROs which translates to ⬆️ DAPSAs in spite of less Rx progression.
-Men more oligoarthritis, axial involvement, higher skin disease.
#ACR24… https://t.co/iapZF0nZWX https://t.co/jZ79WfxZwh
Links:
Adela Castro AdelaCastro222 ( View Tweet)
🔥Sex matters in PsA
🔑Differences in :
➡️clinical phenotypes
➡️radiographic progression
➡️disease impact
➡️pt perception of disease
➡️response to Rx
#ACR24 @RheumNow https://t.co/iOXQmoxgp0
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
The 3-4-5 rule for positive MRI in axSpA remains.
The MRI lesion cut-offs demonstrated high performance across different features of axSpA (PsO, AAU,IBD).
Deep fat and deep sclerosis high specificity for axSpA.
#Abst0821 #ACR24 @RheumNow https://t.co/4JM5MHrB8z
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Factors associated w/ secukinumab response in PsA?
Analysis of 2.7k pt in EuroSpA
Associated w/ favorable response
❗️elevated CRP >10 mg/L
❗️fewer prev tx
Associated w/ lower response:
❗️smoking
❗️higher patient global score / HAQ
@RheumNow #ACR24 Abstr 2325
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE
Links:
Dr. John Cush RheumNow ( View Tweet)
Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs?
≥5% weight loss, after taking a med, led to better disease activity & QoL
Data may inform RCTs to explore effect of these meds in RMDs
Ab0845 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
LTE of deucravacitinib trials in psoriasis. Remarkable & frankly surprising (to me) persistence of benefit Very encouraging for patients who start TYKs, looks like those who respond may have prolonged benefit #ACR24 @RheumNow Abstr#0290 #ACRBest https://t.co/kao4vqpPTQ
Links:
Mike Putman EBRheum ( View Tweet)
#0600
🔬BKZ achieves sustained impact in PsA
➡️ BE OPTIMAL & BE COMPLETE trials:BKZ 160 mg Q4W bDMARD-naïve & TNFi-IR PsA pts
➡️Pain,function,fatigue & skin showed greatest & sustained reductions @ 2 yrs👇
🎯BKZ offers sustained response in 🔑PsA domains
#ACR24 @RheumNow https://t.co/uhzZoOrr3H
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Does apremilast have cardiometabolic benefits?
Abstract 0598: In PsA patients, 1-year treatment with apremilast associated w/ ↓ body fat mass, including android fat, and was linked w/ improved disease activity (DAS28-CRP). #ACR24 @RheumNow https://t.co/11n4gQN7Xo
Akhil Sood MD AkhilSoodMD ( View Tweet)
#0588
🔬 Sex Differences in PsA
➡️n=1405, pooled RCT data
♀️49%: Milder PsO (PASI 7.8 v 11.5), higher BMI, longer PsA duration,⬆️ fatigue/pain vs ♂️
♀️worse QoL/functional impairment
♂️More dactylitis (45% v 37%)
🩺 Sex-specific factors matter in PsA
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#0589
🔬Time to Response in PsA Domains: Secukinumab
➡️Post-hoc analyses, n=1366
🔑Median time (wks) to MCID 👇
🔴Systemic inflammation <2
🔴MSK: ~4 wks (enthesitis~12)
🔴Fatigue~7–8
🔴PASI75~8–12; nails ~24
🩺 Rapid MSK & QoL benefits precede skin/nail
#ACR24 @RheumNow https://t.co/WfqkryA1CC
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#0585 🔬PsA/axSpA: TNFi Cycling v IL-17Ai Switch
➡️470 pts: Switchers to IL-17Ai had similar/better outcomes v TNFi cyclers @ 6 mo
➡️PsA: Switchers had improved arthritis/psoriasis(-5.0, p=0.02)
➡️axSpA: Switchers had improved fatigue(-9.4, p=0.01)
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and as effective as TNFi and JAKi. No much differences seen at 12m. Abst#0076 #ACR24 @RheumNow https://t.co/dScwsmkDOe
Adela Castro AdelaCastro222 ( View Tweet)
#0584🔬Real-World PsA Study:Tofacitinib
➡️141 pts:47% mono,53% combo;~70% on Rx @ 6mo
➡️Similar ⬆️in disease outcomes (cDAPSA LDA: 31% mono vs 21% combo; MDA ~16%).
➡️No significant differences mono v combo outcomes
🩺Tofa effective in diverse PsA population
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
With many treatments for #PsA and #PsO, what are the prescribing trends?
Abstract 0604: TNF inhibitors remain the most common (~60%), but over the past 10 years, IL-17i use rose from 0.2% to 19%, and IL-23i from 0.1% to 39.7%! #ACR24 @RheumNow https://t.co/4TnCAkHfuY
Akhil Sood MD AkhilSoodMD ( View Tweet)
